biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Aug 06, 2017 4:08pm

108 Views

Post# 26552552

RE:RE:Non-Human Primates

....BTI may very well bring a drug to Market--and it could be a 100x's today's price--, but really, statistically, their probability of doing so is less than 10% and years away....

I think it's quite a bit higher than 10% and less time than you think. You're applying numbers from looking at companies that are developing a new drug. Transcend is not entirely comparable to those.

As far as the transported drugs go, the possibility of success varies a ton. Some new Alzheimer's drug? Who knows. But Herceptin and LSD enzymes have already been introduced intrathecally to the brain in a number of studies. Trancend just has to transport them. IMO Transcend will likely work in any mammal (as RH has stated).

Bullboard Posts

Options trading in a volatile macro environment